Content |
Hyundai Pharmaceutical Co., LTD. (YOON, Chang-Hyun, CEO) signed the marketing and sales agreement of TachoSill®, the hemostasis surgical patch. Takeda Pharmaceutical Korea Co., LTD. (LEE, Choon Yup, General Manager) grants the exclusive rights to market and distribute in Korea.
Currently Hyundai Pharmaceutical Co., LTD. has been selling Tachocomb, the previous version of TachoSil®, and made this product the number one in Korean hemostasis surgical patch market. From 2013, with the newly introduced and improved product, TachoSil®, Hyundai Pharmaceutical Co., LTD. can continue to consolidate the leading position in hemostasis market. TachoSil® is a collagen sponge that is coated with the active substances human fibrinogen and human thrombin. This new product is used in a variety of surgical procedures to seal tissue and control bleeding, requires little preparation and can be stored at room temperature. It also acts as a support to stitching during surgery on the blood vessels. Compared to Tachocomb, TachoSil® is improved in terms of the safety and maintained the efficacy.
"We are delighted with this agreement," says Mr. YOON, Chang-Hyun, CEO of Hyundai Pharmaceutical Co., LTD. "With the launch, we really have the strong confidence that TachoSil® will successfully become the blockbuster and also we can show our excellent capability as the best partner for the marketing and commercialization of Takeda’s products in Korea.
TachoSil® was approved 5th of September in Korea and under the Korean regulation of blood products, Korean Red Cross holds the license. Takeda will be responsible for the supply and Hyundai Pharmaceutical Co., LTD. will contribute to the distribution and the marketing.
|
|
24 
2/2 
